Non–HDL-C Lowering After Myocardial Infarction: A Race to the Bottom?

An observational study supports early and aggressive lipid lowering after MI.

The lowering of lipoproteins after acute coronary syndrome is essential for managing atherosclerotic risk, but does earlier achievement of lipid target improve patient outcomes? In this retrospective study, researchers evaluated outcomes of early non–HDL-C target achievement (<2.2 mmol/L [85 mg/dL]) after myocardial infarction (MI).

Using a nationwide patient registry in Sweden, investigators identified about 56,000 patients without previous atherosclerotic disease who were admitted for a first MI (median age, 64 years; 26% women). They measured non–HDL-C levels at admission and at 2-month and 1-year follow-ups.

During a median follow-up of 5.4 years, outcomes included the following:

Approximately 17% of patients had a major adverse cardiovasc…

Reviewing Author

Shea E. Hogan, MD, MSCS, FACC, FSCAI, FSVM

Disclosures

Editorial BoardsVascular Medicine

Shea E. Hogan, MD, MSCS, FACC, FSCAI, FSVM

Disclosures

Editorial BoardsVascular Medicine

Non–HDL-C Lowering After Myocardial Infarction: A Race to the Bottom?

Topics

Reviewing Author